Novartis (NYSE:NVS) Earns Daily News Impact Score of 0.31
News headlines about Novartis (NYSE:NVS) have trended positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novartis earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the company an impact score of 49.3622407819799 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Novartis Gets Spark Therapeutics’ Luxterna License Outside US – Nasdaq (nasdaq.com)
- Novartis:FDA Approves Lutathera For Gastroenteropancreatic Neuroendocrine Tumors – Nasdaq (nasdaq.com)
- Recent Insiders Bustle: Community Health Systems, Inc. (CYH), Novartis AG (NVS) – Market Movers (financialqz.com)
- Novartis International AG – Advanced Accelerator Applications Receives FDA … (romandie.com)
- Novartis AG: Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors (twst.com)
Novartis (NYSE:NVS) opened at $93.91 on Monday. Novartis has a 1-year low of $71.50 and a 1-year high of $94.19. The firm has a market cap of $245,960.00, a price-to-earnings ratio of 28.90, a P/E/G ratio of 2.20 and a beta of 0.74. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31.
Several research firms have weighed in on NVS. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. Novartis has an average rating of “Hold” and an average target price of $85.32.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.